Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2
Advanced Healthcare Materials · 2023-10 · 12 (26)
DOI: 10.1002/adhm.202300889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 06.07.2023. Verfasst von Youseong Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. Hauptthemen laut MEDLINE: Viral Vaccines, COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
The coronavirus pandemic has accelerated the development of next‐generation vaccination technology to combat future pandemic outbreaks. Mucosal vaccination effectively protects the mucosal surfaces, the primary sites of viral entry, by inducing the secretion of immunoglobulin A (IgA) and humoral IgG. Here, a dissolving microneedle (DMN) is adopted as a mucosal vaccine delivery platform to directly penetrate the sublingual site, which is rich in antigen‐presenting cells (APCs) and lymphoid tissues. The sublingual dissolving microneedle (SLDMN) vaccination platform comprised a micropillar‐based compartment and a 3D‐printed SLDMN applicator as a substitute for the DMN patch. The penetration efficacy of SLDMNs is assessed using in vitro optical coherence tomography (OCT) and in vivo histological analysis. The efficacy of SLDMN is also evaluated in a vaccine form using the recombinant spike (S1) protein of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Furthermore, SLDMN is used to challenge transgenic mice expressing human angiotensin‐converting enzyme 2 (hACE2) receptors. Its effects are evaluated on antibody production, survival rate, and inflammation attenuation after infection compared to the intramuscular (IM) injections. Overall, SLDMN effectively induced mucosal immunity via IgA secretion, attenuated lung inflammation, and lowered the levels of cytokines and chemokines, which may prevent the “cytokine storm” after SARS‐CoV‐2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
- Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
- Severance Biomedical Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
- JUVIC, 208Ho, 272, Digital-ro, Guro-gu, Seoul, 08389, Republic of Korea.
- Department of Microbiology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
- Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
ORCID-Profile: Hyungil Jung
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Zitieren
APA
Kim, Y., Park, I. H., Shin, J., Choi, J., Jeon, C., Jeon, S., Shin, J. S., & Jung, H. (2023). Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2. Advanced Healthcare Materials, 12(26). https://doi.org/10.1002/adhm.202300889
Vancouver
Kim Y, Park IH, Shin J, Choi J, Jeon C, Jeon S, et al. Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2. Advanced Healthcare Materials. 2023;12(26). doi:10.1002/adhm.202300889
BibTeX
@article{Kim2023,
author = {Kim, Youseong and Park, In Ho and Shin, Jiwoo and Choi, Jaibyung and Jeon, Chansol and Jeon, Seonghun and Shin, Jeon-Soo and Jung, Hyungil},
title = {Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {26},
doi = {10.1002/adhm.202300889}
}
EUVIMED